### COMMISSION OF THE EUROPEAN COMMUNITIES

COM(91) 313 final - SYN 251 and 252 Brussels, 2 August 1991

## Amendment to the proposal for a COUNCIL DIRECTIVE

widening the scope of Directives 65/65/EEC and 75/319/EEC on the approximation of the laws of the Member States on medicinal products and laying down additional provisions on homeopathic medicinal products

## Amendment to the proposal for a COUNCIL DIRECTIVE

widening the scope of Directive 81/851/EEC on the approximation of
the laws of the Member States on veterinary medicinal products
and laying down additional provisions on homeopathic SYN 252
veterinary medicinal products

(presented by the Commission pursuant to Article 149(3) of the EEC-Treaty)

#### EXPLANATORY MEMORANDUM

At its plenary session on 13 June 1991, the European Parliament, on first reading of the co-operation procedure, gave its opinion upon two proposals for Directives relating to homeopathic medicines for human and veterinary use - COM(90)72 of 22.03.90, SYN 251-252.

The Commission has decided, in accordance with Article 149, paragraph 3 of the EEC Treaty, to amend its proposals in order to incorporate into the text 17 out of the 28 amendements adopted by the Parliament.

The primary aims of the amendments accepted by the Commission are :

- to avoid the distortion of competition between manufacturers
- to maintain the principle of a free choice of therapies
- to assimilate anthroposophic medicines as homeopathic medicines when described in an offical pharmacopoela
- to introduce appropriate references to homeopathic and anthroposophic principles.

By contrast, the Commission rejected other amendments for three principal reasons.

Certain of the amendments go far beyond the limits of those proposals which deal with the free movement of medicines, for example; training for and engaging in professional practice, and the way in which the cost of medicines to the patient is met by public funding.

Some amendments show excessive partiality towards particular medical traditions, bearing in mind that the Commission must remain neutral in the debate between "conventional" and "alternative" medicine.

Other amendments would widen excessively the scope of the simplified registration procedure (Article 7), to the extent that a full marketing authorization (Article 9) would become an exception to the normal rule.

It is worth recalling that since 1965 throughout the Community the normal basis for a marketing authorization has been three standard criteria (quality, safety and efficacy) leading the competent authorities to undertake an evaluation of the risks and benefits expected of the medicament in question.

However, the simplified registration procedure, in the form proposed by the Commission, constitutes rather an administrative notification, adequate for homeopathic medicines which do not present any known risk by virtue of their method of administration (oral) and the low concentration of their active constituents, which is fixed at less than one part per million. Manufacturing quality can be verified from the dossier supplied.

The other routes of administration described by the pharmacopoeias, especially injectibles, or stronger concentrations of active constituents, can, in certain cases, expose patients to potential risks and necessitate because of this a more comprehensive authorization procedure based upon an evaluation of the risks and benefits by the competent authorities in accordance with the provisions of Article 9.

### Amendment to the proposal for a COUNCIL DIRECTIVE

widening the scope of Directives 65/65/EEC and 75/319/EEC on the approximation of the laws of the Member States on medicinal products and laying down additional provisions on homeopathic medicinal products

(Presented by the Commission in accordance with article 149, paragraph 3 of EEC Treaty)

Original proposal

Amended proposal

Titles and visas unchanged

First recital

Whereas differences currently existing between the provisions laid down by law, regulation or administrative action in the Member States may hinder trade in homeopathic medicinal products within the Community;

whereas differences currently existing between the provisions laid down by law, regulation or administrative action in the Member States may hinder trade in homeopathic medicinal products within the Community and thus lead to discrimination and distorsion of competition between manufacturers of these products;

2nd recital unchanged Recital 2a (new)

Whereas freedom of choice with regard to therapy needs to be safeguarded; whereas, despite considerable differences in the status of alternative medicines in the various Member States, patients should be quaranteed free access to the therapy of their choice, provided all precautions are taken to ensure the quality and safety of products;

3rd recital unchanged

#### Original proposal

#### Amended proposal

#### Fourth recital

Whereas homeopathic medicine is officially recognized in certain Member States but is only tolerated in other Member States; whereas, therefore, it is appropriate to recognize certain national homeopathic traditions without imposing them throughout the Community;

Whereas homeopathic medicine is officially recognized in certain Member States but is only tolerated in other Member States:

5th, 6th and 7th recitals unchanged

#### Eighth recital

Whereas, having regard to the particular characteristics of these medicinal products, such as their very low content of active principles and the difficulty of applying to them the conventional statistical methods relating to clinical trials, it is appropriate to provide a simplified registration system for those traditional homeopathic medicinal products which are placed on the market without specific therapeutic indications in a preparation which does not present a risk for the patient;

Whereas, having regard to the particular characteristics of these medicinal products, such as their very low content of active principles and the difficulty of applying to them the conventional statistical methods relating to clinical trials, it is appropriate to provide a simplified registration system for those traditional homeopathic medicinal products which are placed on the market without specific therapeutic indications in a preparation and dosage which does not present a risk for the patient;

9th recital unchanged

#### Original proposal

#### Amended proposal

#### Article 1

For the purposes of this Directive "homeopathic medicinal product" shall mean any medicinal product prepared in accordance with a homeopathic manufacturing procedure described by the European Pharmacopoeia, or in the absence thereof, by the official pharmacopoeia of a Member State.

For the purposes of this Directive
"homeopathic medicinal product" shall
mean any pharmaceutical preparation
prepared in accordance with a
homeopathic manufacturing procedure
described by the European
Pharmacopoela, or in the absence
thereof, by the official pharmacopoela
of a Member State.

For the purposes of this Directive
anthroposophical medicinal products
described by an official pharmacopoeia
shall be treated as equivalent to
homeopathic medicinal products.

Homeopathic preparations are produced from products, substances or compositions called homeopathic stocks by successive dilutions.

Homeopathic preparations are produced from products, substances or compositions called homeopathic stocks by successive dilutions and potentiation.

A homeopathic medicinal product may also contain a member of different components.

A homeopathic preparation may contain, with the exception of catalysts, only homeopathic stocks in a minimum dilution of 1:10.

Articles 2, 3, 4, 5 and 6 unchanged
Article 7, paragraph 1 unchanged
Article 7 (2)

Seventh indent a (new)

- a sentence advising the user to consult a competent therapist whilst using the medicinal product if the if the symptoms persist.

Rest of the article unchanged

Article 8, introductory phrase and first three indents

An application for a simplified registration submitted by the person responsible for marketing may cover a series of preparations derived from the same homeopathic stock. The following documents shall be included with the application in order to demonstrate, in particular, the pharmaceutical quality and the batch consistency of the products concerned:

- scientific name of the homeopathic stock, together with a mention of the various routes of administration, pharmaceutical forms and dilutions to be registered;
- dossier describing how the homeopathic stock is obtained and controlled, and Justifying its homeopathic nature, on the basis of an adequate homeopathic bibliography;
- manufacturing and control file for each pharmaceutical form and a description of the method of dilution;

An application for a simplified registration submitted by the person responsible for marketing may cover a series of preparations derived from the same homeopathic stock or stocks. The following documents shall be included with the application in order to demonstrate, in particular, the pharmaceutical quality and the batch consistency of the products concerned:

- scientific name of the homeopathic stock or stocks, together with a mention of the various routes of administration, pharmaceutical forms and strengths to be registered;
- dossier describing how the homeopathic stock or stocks is/are obtained and controlled, and Justifying its homeopathic nature, on the basis of an adequate homeopathic or anthroposophical bibliography;
- manufacturing and control file for each pharmaceutical form and a description of the method of dilution and potentiation;

Rest of the article unchanged

#### Article 9 (1)

- 1. Homeopathic medicinal products other than those referred to in Article 7 shall be authorized and labelled in accordance with the provisions of Articles 5 to 21 of Directive 65/65/EEC and Articles 1 to 7 of Directive 75/319/EEC, including the provisions concerning proof of therapeutic effect.
- 1. Homeopathic and antroposophical medicinal products other than those referred to in Article 7 shall be authorized and labelied pursuant to the provisions of Articles 5 to 21 of Directive 65/65/EEC and Articles 1 to 7 of Directive 75/319/EEC, including the provisions concerning proof of therapeutic effect, in accordance with the basic principles and special nature of homeopathic or anthroposophical medicine.

Article 9(2) unchanged

Article 10 (1) and (2) unchanged

Article 10 (3) (new)

3. Not later than 31 December 1995 the

Commission shall present a report to

the Council and to the European

Parliament concerning the operation of this Directive.

Article 11 unchanged

### Amendment to the proposal for a COUNCIL DIRECTIVE

widening the scope of Directive 81/851/EEC on the approximation of
the laws of the Member States on veterinary medicinal products
and laying down additional provisions on homeopathic
veterinary medicinal products

SYN 252

(presented by the Commission in accordance with Article 149, paragraph 3 of the EEC Treaty)

#### Original proposal

#### Amended proposal

#### First recital

Whereas differences currently existing between the provisions laid down by law, regulation or administrative action by the Member States may hinder trade in homeopathic medicinal products within the Community;

Whereas differences currenity
existing between the provisions laid
down by law, regulation or administrative action in the Member States may
hinder trade in homeopathic medicinal
products within the Community and thus
lead to discrimination and distorsion
of competition between manufacturers of
these products;

2nd recital unchanged Recital 2a (new)

Whereas freedom of choice with regard to therapy needs to be safequarded;

3rd recital unchanged Fourth recital

Whereas homeopathic medicine is officially recognized in certain Member States but is only tolerated in other Member States; whereas, therefore, it is appropriate to recognize certain national homeopathic traditions without imposing them throughout the Community;

Whereas homeopathic medicine is officially recognized in certain Member States but is only tolerated in other Member States;

5th, 6th and 7th recitals unchanged

#### Eighth recital

Whereas, having regard to the particular characteristics of these medicinal products, such as their very low content of active principles and the difficulty of applying to them the conventional statistical methods relating to clinical trials, it is appropriate to provide a simplified registration system for those traditional homeopathic veterinary medicinal products which are placed on the market without specific therapeutic indications in a preparation which does not present a risk for the animal or the consumer of animal products:

Whereas, having regard to the particular characteristics of these medicinal products, such as their very low content of active principles and the difficulty of applying to them the conventional statistical methods relating to clinical trials, it is appropriate to provide a simplified registration system for those traditional homeopathic veterinary medicinal products which are placed on the market without specific therapeutic indications in a preparation and dosage which does not present a risk for the animal or the consumer of animal products:

#### 9th recital unchanged

#### Article 1

For the purposes of this Directive
"homeopathic veterinary medicinal
product" shall mean any veterinary
medicinal product prepared in
accordance with a homeopathic
manufacturing procedure described by
the European Pharmacopoeia, or in
the absence thereof, by the official
pharmacoposia of a Member State.

Homeopathic preparations are produced from products, substances or compositions called homeopathic stocks by successive dilutions.

For the purposes of this Directive
"homeopathic veterinary medicinal
product" shall mean any pharmaceutical
preparation prepared in accordance with
a homeopathic manufacturing procedure
described by the European
Pharmacopoeia, or in the absence
thereof, by the official pharmacopoeia
of a Member State.

Homeopathic preparations are produced from products, substances or compositions called homeopathic stocks by successive dilutions and potentiation. A homeopathic medicinal product may also contain a number of different components.

Homeopathic preparations may contain, with the exception of catalysts, only homeopathic stocks, in a minimum of 1:10.

#### Articles 2, 3, 4, 5, 6 and 7 unchanged

#### Original proposal

#### Amended proposal

#### Article 8

An application for a simplified registration submitted by the person responsible for marketing may cover a series of preparations derived from the same homeopathic stock. The following documents shall be included with the application in order to demonstrate, in particular, the pharmaceutical quality and the batch to batch consistency of the products concerned:

- scientific name of the homeopathic stock, together with a mention of the various routes of administration, pharmaceutical forms and <u>dilutions</u> to be registered;
- dossier described how the stock is obtained and controlled, and justifying its homeopathic nature, on the basis of an adequate homeopathic bibliography;

An application for a simplified registration submitted by the person responsible for marketing may cover a series of preparations derived from the same homeopathic stock or stocks. The following documents shall be included with the application in order to demonstrate, in particular, the pharmaceutical quality and the batch to batch consistency of the products concerned:

- scientific name of the homeopathic stock <u>or stocks</u>, together with a mention of the various routes of administration, pharmaceutical forms and strengths to be registered;
- dossier describing how the homeopathic stock/stocks is/are obtained and controlled, and Justifying its/their homeopathic nature, on the basis of an adequate homeopathic bibliography;

- manufacturing and control file for each pharmaceutical form and a description of the method of dilution;
- manufacturing authorization for the preparations concerned;
- copies of any registrations or authorizations obtained for the same preparations in other Member States;
- one or more specimens or mock-ups of the sales presentation of the preparations to be registered.

- manufacturing and control file for each pharmaceutical form and a description of the method of dilution and potentiation;
- manufacturing authorization for the preparations concerned;
- copies of any registrations or authorizations obtained for the same preparations in other Member States;
- one or more specimens or mock-ups of the sales presentation of the preparations to be registered;
- documents quaranteeing the safety
  of the preparation and, in the case
  of veterinary medicinal products
  intended for administration to foodproducing animals, quaranteeing the
  absence of harmful residues.

#### Article 9

Homeopathic veterinary medicinal products other than those referred to in Article 7 shall be authorized and labelled in accordance with the provisions of Articles 5 to 15 of Directive 81/851/EEC, including the provisions concerning proof of therapeutic effect, and shall be labelled in accordance with the provisions of Articles 43 to 50 of Directive 81/851/EEC.

Homeopathic veterinary medicinal products other than those referred to in Article 7 shall be authorized and labelled in accordance with the provisions of Articles 5 to 15 of Directive 81/851/EEC, including the provisions concerning proof of therapeutic effect, and shall be labelled pursuant to the provisions of Articles 43 to 50 of Directive 81/851/EEC, in accordance with the basic principles and special nature of homeopathic or anthroposophical medicine.

Article 10, paragraphs 1 and 2 unchanged

Article 10 (3) (new)

3. Not later than 31 December 1995
the Commission shall present a
report to the Council and to the
European Parliament concerning
the operation of this Directive.

Article 11 unchanged

COM(91) 313 final

# **DOCUMENTS**

EN

03 05 06

Catalogue number: CB-CO-91-353-EN-C

ISBN 92-77-74898-2

Office for Official Publications of the European Communities L-2985 Luxembourg